Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2016.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 31 - 40 of 68 result(s)
New Molecule

KAE609

cipargamin

Malaria

Infectious diseases

Phase II

>=2021

PfATP4 inhibitor

New Molecule

KAF156

Malaria

Infectious diseases

Phase II

>=2021

Imidazolopiperazines derivative

New Indication

Kisqali®

ribocilib

HR+, HER2 (-) breast cancer (adjuvant, high risk)

Oncology

Phase III

>=2021

CDK4/6 inhibitor

New Indication

Kisqali®

ribocilib

HR+, HER2 (-) breast cancer (adjuvant, intermediate risk)

Oncology

Phase III

>=2021

CDK4/6 inhibitor

New Indication

Kisqali® + fulv

ribocilib

HR+, HER2(-) postmenopausal adv. breast cancer 1st/2nd line

Oncology

Phase III

2018

CDK4/6 inhibitor

New Indication

Kisqali® + tmx + gsn/or NSAI + gsn

ribocilib

HR+, HER2(-) premenopausal adv. breast cancer 1st line

Oncology

Phase III

2018

CDK4/6 inhibitor

Biosimilars

LA-EP2006

pegfilgrastim, US

Chemotherapy-induced neutropenia and others (same as originator)

Biosimilars

Phase II

2019

Pegylated granulocyte colony-stimulating factor

Biosimilars

LA-EP2006

pegfilgrastim, EU

Chemotherapy-induced neutropenia and others (same as originator)

Biosimilars

Submission

2017

Pegylated granulocyte colony-stimulating factor

New Indication

LAM320

clofazimine

Multi-drug resistant tuberculosis

Infectious diseases

Phase III

2018

Mycobacterial DNA binding

New Molecule

LCI699

osilodrostat

Cushing’s disease

Oncology

Phase III

2018

Aldosterone synthase inhibitor

Pages

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d Lubris LLC transaction announced in April 2017.
e Conatus transaction for exclusive global license for emricasan announced in May 2017.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.